Recalcitrant Issues and New Frontiers in Nano-Pharmacology

被引：38

作者：

Bhardwaj, Vinay ^{[1
]}

Kaushik, Ajeet ^{[2
]}

Khatib, Ziad M. ^{[3
]}

Nair, Madhavan ^{[4
]}

McGoron, Anthony J. ^{[5
]}

机构：

[1] Coll New Jersey, Dept Biomed Engn, Ewing, NJ 08618 USA

[2] Florida Polytech Univ, Dept Nat Sci, Lakeland, FL USA

[3] Nicklaus Childrens Hosp, Dept Pediat, Div Hematol Oncol, Miami, FL USA

[4] Florida Int Univ, Herbert Wertheim Coll Med, Ctr Personalized Nanomed, Miami, FL 33199 USA

[5] Florida Int Univ, Dept Biomed Engn, Miami, FL 33199 USA

来源：

FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷

关键词：

nanoparticles; theranostics; research and development; nano-based drugs; Doxil; nanomedicine; DRUG-DELIVERY; IN-VIVO; LIPOSOMAL DOXORUBICIN; BREAST-CANCER; TIME; NANOPARTICLES; NANOMEDICINE; FORMULATIONS; SPECTROSCOPY; CHALLENGES;

D O I：

10.3389/fphar.2019.01369

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Packaging of old pharma drugs into new packaging "nanoparticles" is called nano-pharmacology and the products are called nano-based drugs. The inception of nano-pharmacology research and development (R&D) is marked by the approval of the first nano-based drug Doxil (R) in 1995 by the Food and Drug Administration. However, even after more than two decades, today, there are only similar to 20 nano-based drugs in the market to treat cancers and brain diseases. In this article we share the perspectives of nanotechnology scientists, engineers, and clinicians on the roadblocks in nano-pharmacology R&D. Also, we share our opinion on new frontiers in the field of nano-pharmacology R&D that may allow rapid and efficient transfer of nano-pharma technologies from R&D to market.

引用

页数：9

共 70 条

[1] The Flaws and Human Harms of Animal Experimentation [J].

Akhtar, Aysha .

CAMBRIDGE QUARTERLY OF HEALTHCARE ETHICS, 2015, 24 (04) :407-419

[2] Regulating nanomedicine [J].

不详 .

NATURE MATERIALS, 2007, 6 (04) :249-249

[3]

[Anonymous], 2013, NIH Record

[4] Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo [J].

Ashton, Susan ;

Song, Young Ho ;

Nolan, Jim ;

Cadogan, Elaine ;

Murray, Jim ;

Odedra, Rajesh ;

Foster, John ;

Hall, Peter A. ;

Low, Susan ;

Taylor, Paula ;

Ellston, Rebecca ;

Polanska, Urszula M. ;

Wilson, Joanne ;

Howes, Colin ;

Smith, Aaron ;

Goodwin, Richard J. A. ;

Swales, John G. ;

Strittmatter, Nicole ;

Takats, Zoltan ;

Nilsson, Anna ;

Andren, Per ;

Trueman, Dawn ;

Walker, Mike ;

Reimer, Corinne L. ;

Troiano, Greg ;

Parsons, Donald ;

De Witt, David ;

Ashford, Marianne ;

Hrkach, Jeff ;

Zale, Stephen ;

Jewsbury, Philip J. ;

Barry, Simon T. .

SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (325)

[5]

AUTIO KA, 2016, J CLIN ONCOL S, V34

[6]

Barenholz Y, 2012, HANDBOOK OF HARNESSING BIOMATERIALS IN NANOMEDICINE: PREPARATION, TOXICITY, AND APPLICATIONS, P335

[7] Doxil® - The first FDA-approved nano-drug: Lessons learned [J].

Barenholz, Yechezkel .

JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134

[8]

Bawa R., 2016, HDB CLIN NANOMEDICIN, DOI [10.1201/b19910, DOI 10.1201/B19910]

[9] Regulating Nanomedicine - Can the FDA Handle It? [J].

Bawa, Raj .

CURRENT DRUG DELIVERY, 2011, 8 (03) :227-234

[10] Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity [J].

Bennett, Neal K. ;

Chmielowski, Rebecca ;

Abdelhamid, Dalia S. ;

Faig, Jonathan J. ;

Francis, Nicola ;

Baum, Jean ;

Pang, Zhiping P. ;

Uhrich, Kathryn E. ;

Moghe, Prabhas V. .

BIOMATERIALS, 2016, 111 :179-189

← 1 2 3 4 5 6 7 →